National Institute for Health and Clinical Excellence (NICE) and Targeted Therapies for Metastatic Renal Cell Carcinoma (Feature Article) (Report)
Advances in Oncology 2010, Dec, 5, 4
-
- 2,99 €
-
- 2,99 €
Descrizione dell’editore
Introduction Renal cell carcinoma (RCC) accounts for 2% of all cancer deaths in the United Kingdom [1]. Whilst RCC localised to the kidney can be treated with radical nephrectomy [2], those presenting with locally invasive or metastatic cancer provide a far more difficult treatment challenge, as metastatic renal cell carcinoma (mRCC) is poorly responsive to radiotherapy and notoriously chemo resistant [3], with a poor prognosis of 6-10 months median survival [4].
Altri libri di Advances in Oncology
Sutent Satellite Symposium: Held Parallel to the 15th Annual Scientific Meeting of Alexandria Clinical Oncology Department (ACOD) Alexandria, Egypt, 14-16 April 2010: a Report from the Symposium (Conference Report: Renal Cell Carcinoma) (Report)
2010
The Future Is Brite (Feature Article) (Clinical Report)
2009
Aromatase Inhibitors and Evolution of the Lipid Profile (Clinical Report)
2009
Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma: A New Treatment Paradigm for Locally Advanced and Metastatic Disease in the Era of Targeted Therapy (Feature Article) (Clinical Report)
2010
91-Month Analysis of the Inter-Group Exemestane Study (IES): Exemestane After Initial Therapy with Tamoxifen in Postmenopausal Women with Early Breast Cancer (Breast Cancer) (Case Study)
2010
The Use of Epirubicin in Gastric Cancer (Gastrointestinal Cancers)
2010